Stock INKT MINK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.9275 USD +6.46% Intraday chart for MiNK Therapeutics, Inc. +5.84% -13.32%
Mar. 21 Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21 MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
GL
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
AQ
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
MiNK Reports Fourth Quarter and Year-End 2023 Results
GL
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
GL
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
AQ
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
GL
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
AQ
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
CI
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
GL
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer
CI
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.
CI
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
GL
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
AQ
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
CI
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
GL
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
AQ
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
CI
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INKT Stock
  4. News MiNK Therapeutics, Inc.